Results 91 to 100 of about 18,100 (230)
Research progress on phosphodiesterase 4 inhibitors in the treatment of palmoplantar pustulosis
Pifu-xingbing zhenliaoxue zazhiPalmoplantar pustulosis (PPP) is a chronic recurrent inflammatory skin disease. Existing therapeutic methods cannot meet the demand by patients. Phosphodiesterase-4 (PDE-4) is a key enzyme involved in the balance of immunocytes.
YAO Xinyi +3 more
doaj +1 more source
Liquen nítido geneneralizado associado à síndrome de Down: relato de caso [PDF]
, 2012 Lichen nitidus is a disease of unknown etiology, characterized by flesh-colored, shiny papules of 1-2 mm and generally asymptomatic or with mild pruritus. The most common sites of occurrence are genitalia, upper limbs, trunk and abdomen.
Botelho, Luciane Francisca Fernandes +4 more
core +4 more sources
European Journal of Neurology, Volume 33, Issue 5, May 2026.This study investigates four Chinese families with congenital insensitivity to pain with anhidrosis (CIPA). Through next‐generation sequencing, we identified seven NTRK1 variants, including two novel mutations. Functional characterization of five identified missense and indel variants revealed distinct disruptions in the NGF‐TrkA pathway, ranging from ...
Yaqiong Ren +9 more
wiley +1 more source
Adult-onset porokeratotic eccrine ostial and dermal duct nevus:dermatoscopic findings and treatment with tazarotene [PDF]
, 2020 Porokeratotic eccrine ostial and dermal duct nevus (PEODDN) is a rare dermatosis initially described as ‘comedo nevus’ and renamed ‘PEODDN’; it has also been referred to as linear eccrine nevus with comedones, porokeratotic eccrine ostial and hair ...
Alomran, Husain, Kanitakis, Jean
core
Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page 887-899, May 2026.This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami +6 more
wiley +1 more source
Acta Dermato-Venereologica, 2017 Differential diagnosis of palmoplantar non-pustular psoriasis and chronic allergic contact dermatitis (ACD) and the combination of these conditions, termed "eczema in psoriatico" (EIP), is difficult, especially in cases of isolated involvement.
Malgorzata Kolesnik +4 more
doaj +1 more source
Epidermolysis bullosa simplex with mottled pigmentation: a family report and review [PDF]
, 2013 Epidermolysis bullosa simplex with mottled hyperpigmentation (EBS-MP) is an uncommon subtype of EBS. Its clinical features depend on the age of diagnosis, and clinical variations have been described even within family members.
Colmenero, Isabel +9 more
core +3 more sources
Enhancement of Skin Barrier Function Using DYNAMiQ Technology: A Clinical Evaluation
Journal of Cosmetic Dermatology, Volume 25, Issue 5, May 2026.ABSTRACT Background The integrity of the skin barrier is fundamental to maintaining overall skin health, serving as the primary defense against environmental insults. Disruption of this barrier is linked to various dermatological issues, including inflammation, sensitivity, and premature aging.
Klaus Fritz +2 more
wiley +1 more source
Natalizumab-Induced Pustular Psoriasis of Palms and Soles
Dermatology Practical & Conceptual, 2022 Bengisu Ozarslan +3 more
doaj +1 more source
Palmoplantar plaque psoriasis responsive to upadacitinib: A report of two cases
SAGE Open Medical Case ReportsPalmoplantar plaque psoriasis is more resistant to therapy compared to other phenotypes of psoriasis. To our knowledge, there are no reports of the efficacy of Janus kinase (JAK) inhibitors for palmoplantar plaque psoriasis.
Bohmyi Choi +2 more
doaj +1 more source